Comment on Anatomical and functional changes after dexamethasone implant and ranibizumab in diabetic macular edema: a retrospective cohort study

摘要

The study by Mastropasqua et al[1] evaluated the efficacy and safety of ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA, USA; RBZ group) and dexamethasone implant (Ozurdex; Allergan Irvine., CA, USA; DEX group) intravitreal treatments in 50 patients with treatment-naïve center involved diabetic macular edema (DME) by means of functional and morphological assessments during a 6-month follow-up. The best-corrected visual acuity (BCVA) improved significantly in both groups with a greater increase in the DEX group compared to the RBZ group and central macular thickness decreased significantly without statistically significant differences between the 2 groups. The retreatment rate at 180d was 0.65 and 0.50 in the RBZ group and DEX group, respectively. The authors concluded that both treatments were very effective for DME treatment with a lower retreatment rate in the DXE group. We would like to address several challenges that have arisen from this study which can be specifically summarized below.